Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eosinophilic bronchitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Eosinophilic bronchitis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-000495-28 Sponsor Protocol Number: 132 Start Date*: 2017-05-18
    Sponsor Name:Respiratory Research Unit, Bispebjerg University Hospital
    Full Title: SIGNATURE - the 6-gene signature as a predictor of response to treatment in severe asthma and ACOS
    Medical condition: Severe asthma and astma-COPD overlap syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077006 Asthma-COPD overlap syndrome LLT
    20.0 100000004855 10003561 Asthma, unspecified LLT
    20.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000170-30 Sponsor Protocol Number: D3250C00065 Start Date*: 2018-10-17
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma o...
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) SE (Completed) ES (Ongoing) PL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003924-35 Sponsor Protocol Number: 0690 Start Date*: 2019-11-18
    Sponsor Name:University of Leicester
    Full Title: A Randomised Controlled Trial of Mepolizumab Initiated During Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD
    Medical condition: Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    21.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-004143-11 Sponsor Protocol Number: 33103 Start Date*: 2008-12-17
    Sponsor Name:The University of Nottingham
    Full Title: Are macrolide antibiotics effective in chronic idiopathic cough?
    Medical condition: idiopathic chronic cough, defined as cough with no identifiable cause and which has been present for at least 2 monhs.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011224 Cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003509-33 Sponsor Protocol Number: RECONSTRUCT Start Date*: 2016-11-30
    Sponsor Name:Lungemedicinsk Forskningsenhed, Bispebjerg Hospital
    Full Title: The RECONSTRUCT study Reconstructing Disease Mechanisms in Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-003611-10 Sponsor Protocol Number: 213744 Start Date*: 2021-07-06
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with sev...
    Medical condition: Severe uncontrolled asthma with an eosinophilic phenotype
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) PL (Completed) IT (Completed) ES (Ongoing) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-003697-32 Sponsor Protocol Number: 204471 Start Date*: 2015-12-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizum...
    Medical condition: Subjects with severe asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) DE (Completed) SE (Completed) FR (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002513-27 Sponsor Protocol Number: 200862 Start Date*: 2014-11-19
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic...
    Medical condition: Subjects with severe asthma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) BE (Completed) DE (Completed) CZ (Completed) GR (Completed) EE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001832-36 Sponsor Protocol Number: 204959 Start Date*: 2017-05-15
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Stu...
    Medical condition: Severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001831-10 Sponsor Protocol Number: 205667 Start Date*: 2017-02-14
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label, single arm, repeat dose, multi-centre study to evaluate the use of a safety syringe for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma ...
    Medical condition: severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000977-19 Sponsor Protocol Number: D2500C00003 Start Date*: 2016-09-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2 Placebo-Controlled, Randomized, Double Blind, Adaptive Dose Trial of the Safety and Efficacy of Inhaled AZD1419 in Adults With Eosinophilic, Moderate to Severe Asthma
    Medical condition: AZD1419 is planned to be developed as a potential disease-modifying therapy for asthma. Target population is patients with moderate to severe eosinophilic asthma.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002361-32 Sponsor Protocol Number: 201810 Start Date*: 2016-04-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-center, randomized, double-blind, placebo controlled, parallel group study to compare cessation versus continuation of long-term mepolizumab treatment in patients with severe eosinophilic a...
    Medical condition: severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) RO (Ongoing) FR (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000801-38 Sponsor Protocol Number: KFL3502 Start Date*: 2016-02-19
    Sponsor Name:Mundipharma Research Limited
    Full Title: A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in sub...
    Medical condition: Asthma Bronciale
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003555 Asthma bronchial LLT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-018249-78 Sponsor Protocol Number: 09115 Start Date*: 2010-05-14
    Sponsor Name:University of Nottingham
    Full Title: Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma
    Medical condition: Refractory Asthma
    Disease: Version SOC Term Classification Code Term Level
    12. 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020126-17 Sponsor Protocol Number: MI-CP220/D3250L00001 Start Date*: 2011-01-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b, dose-ranging study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma
    Medical condition: Uncontrolled Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-003632-25 Sponsor Protocol Number: 206713 Start Date*: 2021-06-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with sev...
    Medical condition: Severe uncontrolled asthma with an eosinophilic phenotype
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Completed) PL (Completed) IT (Completed) ES (Ongoing) IE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004661-23 Sponsor Protocol Number: C38072-AS-30066 Start Date*: 2017-03-15
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label Extension Safety Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older with Severe Eosinophilic Asthma
    Medical condition: Uncontrolled Asthma & elevated blood Eosinophils
    Disease: Version SOC Term Classification Code Term Level
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) FR (Completed) ES (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000275-14 Sponsor Protocol Number: GB29260 Start Date*: 2014-08-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II, randomized, double-blind, placebo-controlled bronchoscopy study to evaluate the effects of Lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhal...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005097-52 Sponsor Protocol Number: 109405 Start Date*: 2007-04-25
    Sponsor Name:Adelaide & Meath Hospital [...]
    1. Adelaide & Meath Hospital
    2. Adelaide & Meath Hospital, incorporating the National Children's hospital
    Full Title: A Single-Centre, Randomised, double-blind, two month Interventional Parallel group Study Assessing the in vivo synergy of salmeterol xinafoate/fluticasone propionate (50/250 μg twice daily) via a ...
    Medical condition: Eosinophilic inflammation in the lungs of adult subjects > 18 years old who have moderate bronchial asthma.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004334-38 Sponsor Protocol Number: 212895 Start Date*: 2022-05-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phe...
    Medical condition: Severe asthma with an eosinophilic phenotype
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 11:43:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA